tbuckley/cabot-search huggingface dataset:
Rechallenge of malignant gliomas with temozolomide —Can it be effective?
Authors: H. M. Strik, J. H. Buhk, H. C. Bock, M. Nitsche, A. Giese, M. Baehr
Journal: Journal of Clinical Oncology (2007)

2072 Background: No standard treatment of recurrent malignant glioma is established. Moreover, it is unclear if a rechallenge with temozolomide is effective. We present here feasibility and first treatment results of a dose-dense, individually dose adapted 21-day regimen with temozolomide. Methods: 13 consecutive patients with recurrent malignant gliomas (11 glioblastomas [GBM], 1 anaplastic astrocytoma, 1 anaplastic oligodendroglioma) were treated. The basic data are: median time to first relapse 8.3 months; median Karnofsky performance status 60% (7 x 50+60%; 6 x 70–100%); median age 52.2 (32–73) years; gender: 9 males (69%), 4 females (31%). All patients were pretreated with radiochemotherapy and temozolomide 200mg/m 2 days 1–5/28 in first line. In eight of the 13 patients, therapy was switched without delay to the dose-dense schedule: temozolomide 100mg/m 2 day 1–21/28. During treatment, the dosage was adapted individually, aiming towards total leukocyte counts of approximately 4,000/μL. Results: The 21/28-days regimen was better tolerated than the 5/28-days schedule regarding nausea and fatigue. Blood counts decreased continuously, enabling a gradual dose adaptation. The dosage was kept at 100mg/m 2 in 9 patients, reduced to 75 mg/m 2 in 3 and gradually increased to 130 mg/m 2 in 1 patient. Hematotoxicity was WHO grade 3 in 2, and grade 4 in 1 patient without clinical signs. One patient had a pneumonia WHO grade 4 in the terminal stage of the disease several weeks after discontinuation of the chemotherapy. Response after 2 months was: 3 partial and 1 complete remission (31%; GBM only: 18%), 4 stable diseases (31%), 5 progressive diseases (38%). The progression free survival at 6 months (PFS) was 54.5% (GBM: 44%). In the 9 glioblastoma patients with an observation period of more than 6 months, the median survival time after relapse was 35.8 weeks, median overall survival 18.2 months. Conclusions: Second line treatment with dose dense temozolomide at 100 mg/m 2 day 1–21/28 and individual dose adaptation is feasible for recurrent malignant gliomas. Even in this series with relatively unfavorable prognostic criteria, the rate of objective responses and 6-months PFS after rechallenge with temozolomide compares well with other series. The results will be controlled in a prospective study. No significant financial relationships to disclose.
A New Strategy to Overcome the Cell Dose Barrier to Umbilical Cord Blood Transplants: A Proof of Early Hematopoietic Reconstitution By Combined Multiple Units of Allogeneic Stem/Progenitor Cells
Authors: Takashi Ishida, Makoto Otsu, Satoshi Takahashi, Masaaki Higashihara, Hiromitsu Nakauchi
Journal: Blood (2014)
Mould‐sensitized adults have lower Th2 cytokines and a higher prevalence of asthma than those sensitized to other aeroallergens
Authors: M. C. Matheson, J. C. Reece, R. K. Kandane‐Rathnayake, M. L. K. Tang, J. A. Simpson, I. H. Feather, M. C. Southey, H. Tsimiklis, J. L. Hopper, S. C. Morrison, G. G. Giles, E. H. Walters, S. C. Dharmage
Journal: Allergy (2016)

Evidence suggests that specific allergen sensitizations are associated with different allergic diseases which may reflect different underlying immune profiles. We aimed to examine the cytokine profiles of individuals sensitized to eight common aeroallergens.We used data from the Tasmanian Longitudinal Health Study a population-based cohort study of 45-year-olds. Serum cytokines (IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α) were measured in 1157 subjects using the LINCOplex assays. Participants underwent skin prick testing for house dust mite, cat, grasses and moulds. Multivariable linear regression was used to compare serum cytokine levels between sensitized and nonatopic subjects.The prevalence of allergic sensitization to any aeroallergen was 51% (95% CI 47-54). Being sensitized to any aeroallergen was strongly associated with current asthma (OR = 3.7, 95% CI 2.6-5.3), and being sensitized to any moulds was associated with a very high risk of current asthma (OR = 6.40, 95% CI 4.06-10.1). The geometric mean (GM) levels of Th2 cytokines (IL-4, IL-5 and IL-6) for adults sensitized to Cladosporium were significantly lower than the levels for nonatopic individuals (IL-4 ratio of GMs = 0.25, 95% CI 0.10-0.62, P = 0.003; IL-5 GM = 0.55, 95% CI 0.30-0.99, P = 0.05; and IL-6 GM = 0.50, 95% CI 0.24-1.07, P = 0.07). Individuals sensitized to other aeroallergens all showed elevated Th2 cytokine levels.Our study is the first large population-based study to demonstrate reduced Th2 cytokines levels in people sensitized to mould. Underlying biological mechanisms driving allergic inflammatory responses in adults sensitized to moulds may differ from those sensitized to other aeroallergens. These findings suggest that it may be necessary to tailor treatments in individuals sensitized to moulds compared with other aeroallergens in order to optimize outcomes.
OP20 Hepatocytes and cholangiocytes do not have significant telomere shortening with increasing chronological age in normal livers
Authors: S Verma, P Tachtazisis, S Penrhyn-Lowe, C Scarpini, N Coleman, G Alexander
Journal: Gut (2010)

Introduction  Telomeres, which cap and protect chromosomal DNA, shorten with each cell division reaching a critical point eventually when the cell is arrested in G1 phase and enters a state of cellular senescence. This process has been demonstrated in both normal ageing and chronic disease in diverse tissues. Murine studies demonstrated that telomere shortening within the liver predisposes to cirrhosis. Few studies have examined the effect of increasing age on telomere length within healthy human liver. Measuring telomere length in liver by Southern blotting assumes that results are representative for hepatocytes. However, liver comprises a diverse group of cells including hepatocytes, Kupffer cells, stellate cells, lymphocytes and cholangiocytes. A large volume four colour quantitative fluorescent in situ hybridisation (Q-FISH) technique was developed to measure telomere length within each cell type.  Aim  To determine the effect of increasing age upon telomere length in healthy liver within hepatocytes, Kupffer cells, stellate cells, CD4 or CD8 lymphocytes and cholangiocytes.  Method  Q-FISH was performed on paraffin-embedded tissue from 73 “time zero” liver biopsies obtained at liver transplantation from liver donors selected carefully for the absence of reperfusion injury and to include a wide age range (5–79 years). Hepatocytes, Kupffer cells, hepatic stellate cells, CD4 or CD8 lymphocytes and cholangiocytes were identified with monoclonal antibodies to Hepar-1, CD68, SMA, CD4, CD8 and CK-19, respectively; nuclei were counterstained with DAPI and telomeres identified with a specific Cy5-labelled PNA probe. Image acquisition and data analysis were performed with Olympus ScanR microscope and software. Mean telomere fluorescent intensity was measured and analysed using linear regression on GraphPad PRISM 5.0.  Results  The Q-FISH methodology enabled large volume analysis of telomeres in various cell lineages within paraffin-embedded liver sections. A mean 40 000 hepatocytes, 30 000 Kupffer cells, 15 000 cholangiocytes and 4000 hepatic stellate cells, intrahepatic CD4 and CD8 lymphocytes were analysed per liver. Hepatic stellate cells had the longest telomeres at all ages whilst the others cell types had similar telomere lengths. Telomeres within Kupffer cells and stellate cells in healthy liver shortened, as might be expected, with increasing age (p=0.024 and p  Conclusion  Cells within the healthy liver do not age equally. The disparity between age-related telomere shortening in Kupffer cells and stellate cells and maintained telomere length with age in cholangiocytes, hepatocytes and intrahepatic lymphocytes was unexpected but may reflect low turn over in hepatocytes and cholangiocytes. The absence of an effect of age on these cell lineages suggests that the potential for regeneration is maintained with age and has important implications for the choice of control tissues in studies of hepatic ageing.
418O Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC
Authors: N. Rizvi, A. Balmanoukian, S.B. Goldberg, J. Chaft, R.E. Sanborn, M.C. Rebelatto, R. Narwal, P.B. Robbins, Y. Gu, J.J. Karakunnel, S. Antonia
Journal: Annals of Oncology (2015)
Intracellular and Extracellular Particles in Tissue Cultures Inoculated With Parotid-Tumor Agent (Polyoma Virus)
Authors: William G. Banfield, Clyde J. Dawe, Darlene C. Brindley
Journal: JNCI Journal of the National Cancer Institute (1959)

Cell cultures of murine lymphoma strain P388 D1 were inoculated with parotid-tumor agent (polyoma virus) and examined with the electron microscope after the appearance of cytopathogenic effect. Intranuclear, intracytoplasmic, and extracellular spherical particles of relatively uniform appearance, measuring approximately 27 to 35 mµ in diameter, were found. Similar particles did not occur in uninfected control cultures. Newborn C3Hf/BiLw mice inoculated with the infected cultures developed salivary-gland tumors and multiple tumors of other types associated with this agent, whereas mice receiving control cultures did not. A second type of particle similar to that described by Dmochowski and Grey in murine and human leukemias was found both in test and control cultures. This type of particle was not associated with leukemia in the present study.
Pictorial review of wrist injuries in the elite golfer
Authors: PJ O'Connor, R Campbell, AK Bharath, D Campbell, R Hawkes, P Robinson
Journal: British Journal of Sports Medicine (2016)

Golf is growing in popularity, with some 20 million players predicted to be playing in China alone by 2020.1 Its inclusion as an Olympic sport will only serve to increase the sport's international profile and popularity. At the pinnacle of the sport is a small group of elite professional golfers who, when compared with amateurs, have more reproducible swing mechanics, and generate greater forces and increased repetitive loads, which are thought to result in differing injury rates and patterns from those of the amateur.2 A study carried out by Hawkes et al 3 on professional golfers reported that the majority of injuries were in the leading wrist, with ulnar-sided injury most common.

This article will review the biomechanics, clinical presentation and imaging findings in the commonest wrist injuries encountered by the examining sports physician in the elite golfer. We classify these wrist injuries by the anatomical localisation of symptoms; ulnar-sided, radial-sided and dorsal injuries will be described. The reader is also encouraged to review the YouTube video on wrist examination.4

The wrists link the body to the golf club and form the final component of a kinetic chain—composed of the hips, spine and shoulders—which powers and controls the golf swing. The lead side of the body is generally viewed as being more active during the golf swing, providing power to the golf swing; as a result, it is generally more prone to injury. A detailed analysis of wrist biomechanics during the golf swing is beyond the scope of this paper, and this work has already been described several times previously.5–7 An overview of wrist movement through the swing does, however, provide a useful framework on which to consider pathology.

The lead (or non-dominant wrist) begins the golf swing in a position of ulnar deviation when addressing …
Targeted Drug Delivery: Carbon‐Quantum‐Dots‐Loaded Mesoporous Silica Nanocarriers with pH‐Switchable Zwitterionic Surface and Enzyme‐Responsive Pore‐Cap for Targeted Imaging and Drug Delivery to Tumor (Adv. Healthcare Mater. 12/2016)
Authors: Zhongning Liu, Xin Chen, Xiaojin Zhang, John Justin Gooding, Yongsheng Zhou
Journal: Advanced Healthcare Materials (2016)

On page 1401 X. Chen, X. Zhang, Y. Zhou, and co-workers describe the synthesis of mesoporous silica nanocarriers with pH-switchable antifouling zwitterionic surfaces and blue fluorescence that are capable of enzyme-responsive drug release. The system combines tumor treatment and tracking. It shows great potential for cancer treatment, since it exhibits prolonged circulation in the blood system with zero premature release while offering selective cellular uptake, tumor labeling, and intracellular drug release in tumor tissue.
Advanced or recurrent endometrial cancer (EC) and co-occurring mutations in multiple oncogenic pathways.
Authors: Alexandra Leary, Shanna Rajpar, Sandrine Mace, Pierre Duvillard, Annie Rey, Sebastien Gouy, Christine Haie-Meder, Patricia Pautier, Coumaran Egile, Isabelle Miran, Ludovic Lacroix, Catherine Lhomme
Journal: Journal of Clinical Oncology (2014)

5514 Background: The prognosis of EC is excellent and mainly driven by early stage type I EC. However, for type II or advanced EC, relapses are frequent. Genomic studies so far included mainly early stage good prognosis primary tumors. Here, we aimed to characterize genetic alterations in high risk advanced or recurrent EC, determine the rate of co-occurring mutations and evaluate concordance between primary and metastatic sites. Methods: High risk EC patients were identified from the IGR tumor bank and defined as stage III or IV, or any stage with subsequent relapse. Samples with >30% cellularity were subjected to Sanger sequencing on 79 exons from 13 genes (KRAS, NRAS, HRAS, BRAF, AKT1, PIK3CA, PIK3R1, PIK3R2, PTEN, STK11, ESR1, TP53, FGFR2). Mutation calls were confirmed by an independent analysis. Results: 75 samples from 57 patients (pts) representative of high risk EC were identified: 49% (28/57) were type II EC, 70% were stage III/IV and the remaining stage I/II pts had all relapsed. By comparison, the TCGA set included 75% stage I/II pts of which only 11% had relapsed. 69 samples from 54 pts qualified for DNA analysis including 13 pts with both primary and metastatic tumors. 80% (43/54) of pts harbored at least one mutation (M+). The most frequent mutation was TP53 in 35% (19/54) of pts. Alterations of core components of the PI3K pathway (AKT1, PIK3CA, PIK3R1, PIK3R2, PTEN, STK11) were identified in 65% of pts (81% and 48% for type I vs. type II EC). RAS M+ were identified in 24%. 65% of pts had >1 M+ including concomitant TP53 M+ and PI3K related M+ (18%), concomitant TP53 M+ and RAS M+ (7%); concomitant PI3K-related M+ and RAS M+ (15%), concomitant FGFR2 M+ and PI3K-related M+ (9%) or concomitant FGFR2 M+ and RAS M+ (4%). Among 13 cases with available primary and metastatic tumor, discordant M+ were found in 5/13 (38%). Conclusions: Co-occurring actionable oncogenic mutations are frequent in high risk advanced or recurrent EC. This may explain disappointing results with single agent targeted therapies in EC, but provides the rationale for trials investigating combined inhibition of PI3K and MEK, PI3K and FGFR, or MEK and FGFR in molecularly selected EC. Supported by a research grant from Sanofi Oncology.
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria
Authors: Ganesh Raghu, Athol U. Wells, Andrew G. Nicholson, Luca Richeldi, Kevin R. Flaherty, Florence Le Maulf, Susanne Stowasser, Rozsa Schlenker-Herceg, David M. Hansell
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical features of usual interstitial pneumonia (UIP), on high-resolution computed tomography (HRCT). Thus, the patients in these trials represented patients with definite UIP and a large subgroup of patients with possible UIP.To investigate the potential impact of diagnostic subgroups on the progression of IPF and the effect of nintedanib.We conducted a post hoc subgroup analysis of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy versus patients without either, using pooled data from the INPULSIS trials.Seven hundred twenty-three (68.1%) patients had honeycombing and/or biopsy, and 338 (31.9%) patients had no honeycombing or biopsy. In these subgroups, respectively, the adjusted annual rate of decline in FVC in patients treated with placebo was -225.7 and -221.0 ml/yr, and the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 117.0 ml/yr (95% confidence interval, 76.3-157.8) and 98.9 ml/yr (95% confidence interval, 36.4-161.5). There was no significant treatment-by-subgroup interaction (P = 0.8139). Adverse events were similar between the subgroups.Patients with IPF diagnosed in clinical practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lung biopsy had disease that progressed in a similar way, and responded similarly to nintedanib, to that of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy.
The Histamine Content of Some Experimental Tumors
Authors: Sanford M. Rosenthal
Journal: JNCI Journal of the National Cancer Institute (1949)

Journal Article The Histamine Content of Some Experimental Tumors Get access Sanford M. Rosenthal Sanford M. Rosenthal Experimental Biology and Medicine Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 1, August 1949, Pages 89–91, https://doi.org/10.1093/jnci/10.1.89 Published: 01 August 1949 Article history Received: 01 March 1949 Published: 01 August 1949
춘계학술대회 : 포스터발표 ; 간경변증 : 복수 치료를 위해 입원이 필요했던 간경변증 환자들의 치료 성적 및 예후: 최근 10년간의 자료 분석
Authors: 김승업, 한광협, 남정모, 김도영, 백용한, 이관식, 전재윤, 안상훈
Journal: Clinical and Molecular Hepatology (2007)
The Case for Biennial Retinopathy Screening in Children and Adolescents
Authors: Ann M. Maguire, Albert K.F. Chan, Janine M. Cusumano, Stephen J. Hing, Maria E. Craig, Martin Silink, Neville J. Howard, Kim C. Donaghue
Journal: Diabetes Care (2005)

In response to the letter from Amin (1), we provide further details on the risk factors for progression and regression of retinopathy in our natural history study (2). Of 136 patients with retinopathy at baseline, 72 progressed or persisted compared with 50 patients (37%) who regressed to no retinopathy and 14 who regressed to a lower grade of retinopathy after …
Functional Modification of Fibrous PCL Scaffolds with Fusion Protein VEGF‐HGFI Enhanced Cellularization and Vascularization
Authors: Liqiang Zhao, Shaoyang Ma, Yiwa Pan, Qiuying Zhang, Kai Wang, Dongmin Song, Xiangxiang Wang, Guowei Feng, Ruming Liu, Haijin Xu, Jun Zhang, Mingqiang Qiao, Deling Kong
Journal: Advanced Healthcare Materials (2016)

The lack of efficient vascularization within frequently used poly(ε-caprolactone) (PCL) scaffolds has hindered their application in tissue engineering. Hydrophobin HGFI, an amphiphilic protein, can form a self-assembly layer on the surface of PCL scaffolds and convert their wettability. In this study, a fusion protein consisting of HGFI and vascular endothelial growth factor (VEGF) is prepared by Pichia pastoris expression system. Sodium dodecyl sulface-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting confirm that the VEGF-HGFI is successfully isolated and purified. Transmission electron microscope and water contact angle measurement demonstrate that VEGF-HGFI can form a self-assembly layer with about 25 nm in thickness on electrospun PCL fibers and increase their hydrophilicity. VEGF-HGFI modification can effectively enhance the adhesion, migration, and proliferation of human umbilical vein endothelial cells. Near-infrared fluorescence imaging shows that the VEGF-HGFI modification on PCL scaffolds can exist at least 21 d in vitro and at least 14 d in vivo. Bioluminescence imaging shows that VEGF-HGFI can effectively activate vascular endothelial growth factor receptor 2 receptors. Subcutaneous implantation in mice and rats reveal that cellularization and vascularization are significantly improved in VEGF-HGFI modified PCL scaffolds. These results suggest that VEGF-HGFI is a useful molecule for functional modification of scaffolds to enhance cellularization and vascularization in tissue engineering.
478TiP A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease
Authors: J. Wolf, M. Hochmair, J.G. Kattan, M.-K. Ang, E.B. Garon, H.J.M. Groen, R. Heist, K. Ohashi, E. Felip, N. Reguart, R. Garciac Campelo, R. Soo, L. Paz-Ares, F. de Marinis, E.F. Smit, M. Giovannini, M. Squires, X. Cui, Y. Zhang, D. Tan
Journal: Annals of Oncology (2015)
Urinary Incontinence in Adults
Authors: K A McCormick, D K Newman, J Colling, B D Pearson
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic Myeloid Leukemia (CML) Patients With Atypical e1a2 P190 BCR-ABL Translocation Show a Poor Response To Therapy With Tyrosine Kinase Inhibitors (TKI)
Authors: Carme Montoriol-Sabaté, Carolina Martínez-Laperche, P Jiménez-Gámiz, Rosa Collado, Alfredo Minguela-Puras, M.A. Piñán-Francés, B. Bellosillo, Joaquín Martínez-López, Marcos González, María José Larrayoz, MªJose Calasanz, Maria Teresa Gomez-Casares, G. González-Brito, Gloria Soler, Jose Román, A. Jimenez-Velasco, Ismael Buno
Journal: Blood (2013)
Emergence of fox rabies in north-eastern Italy
Authors: P De Benedictis, T Gallo, A Iob, R Coassin, G Squecco, G Ferri, F D'Ancona, S Marangon, I Capua, F Mutinelli
Journal: Eurosurveillance (2008)

Italy has been classified as rabies-free since 1997. In October 2008, two foxes have been diagnosed with rabies in the Province of Udine, north-east Italy. One case of human exposure caused by a bite from one of the foxes has occurred and was properly treated.
The natural history of "chipping"
Authors: N E Zinberg, R C Jacobson
Journal: American Journal of Psychiatry (1976)

The authors present five case histories illustrating controlled use of opiates ("chipping"). Long-term chippers tend to develop consistent social use patterns that permit and also limit use. The authors conclude that controlled use of opiates is possible and that large numbers of people are involved in such use, although they are hard to locate and identify. Controlled users are differentiated from compulsive users more by their development and maintenance of social drug use rituals than by such variables as availability of the drug and personality and family background of the user.